Skip to Content

Clinical Trials Detail

AF-002JG/NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Chemotherapy and Crizotinib

Objective
This is a clinical trial of RO5424802 that will be administered by mouth which is investigational.
IRB Protocol Number
13-2410
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • Lung Cancer
Sponsor(s)
Hoffmann-LaRoche
Contact
AMY BROWN at 720-848-0603
or AMY.M.BROWN@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your disease does not worsen, you do not have severe side effects, and the study remains open. A follow up period will consist of clinic visit and/or phone contact. // Eligibility criteria include but are not limited to 18 years or older with lung cancer.